RxDoctor Payments Data

Alexandra Schwab, OD

Optometrist · Wytheville, VANPI 1568958957

Payments from drug & device makers

$2,826in general payments, 2019–2025

Across 66 payments — averaging $42.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$789
  • Alcon$755
  • Glaukos Corporation$382
  • Kala Pharmaceuticals, Inc.$142
  • Amgen$120
  • Novartis$98
  • plus $540 from 11 others

What the payments were for

  • Speaking & faculty fees$43015%
  • Food & beverage$2,39685%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,826 in reported general payments places this provider in the 80th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$133,652
Medicare patients
585
Services billed
1,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast15$17,515
RestasisCyclosporine21$15,644
LumiganBimatoprost18$8,612
Fluorometholone104$6,892
CequaCyclosporine12$6,836
Latanoprost268$1,945
Prednisolone Acetate20$561
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat33$556
Timolol Maleate54$504
Dorzolamide Hcl33$501
Azelastine Hcl12$438
Brimonidine Tartrate29$250
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$248
Cephalexin11$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$79$24,25639 claims
Bausch & Lomb Americas Inc.Xiidra$16$17,51515 claims
Sun Pharmaceutical Industries Inc.Cequa$61$6,83612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Wytheville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →